Healthcare costs are rising. We can and will do something about it. In the context of the Biomedical Health roadmap, we are developing the tools and expertise needed to help companies, professionals and individuals generate and implement personalised health interventions. This will enable us to help prevent and cure diseases and to cut healthcare costs.
“Our ambition is to understand the causal mechanisms of diseases, and to use this knowledge in the development of well-founded tools and models. We are working with various companies to accelerate the process of developing medicines and functional foods, and to make it more efficient. The same goes for lifestyle interventions tailored to individual situations and needs. In this way, we will help to optimise the quality of care and to cut healthcare costs”, says Ivana Bobeldijk-Pastorova, the Biomedical Health programme manager.
Improving the medicine development process
It takes a lot of time and money to develop new medicines. This process could be improved by using better predictive tools and models in the preclinical process and by improving the design of clinical trials. Biomedical Health develops translational models, measurement tools, and modelling tools to help the developers of medicines and functional foods test the effectiveness and safety of their products more efficiently. This offers a range of benefits, such as reducing the failure rate of medicines in the later stages of their development, which also cuts costs.
Earlier detection and prediction
In an effort to predict someone’s risk of falling ill, we are trying to discover what triggers this disease and how it develops. Armed with a detailed knowledge of biomarkers (measurable indicators that can be detected in blood and other tissues) and with an understanding of disease mechanisms and human behaviour, we will be able to detect metabolic and immune diseases at an earlier stage and predict how they will develop in specific individuals.
Every individual is unique. An overweight individual’s risk of developing diabetes and other complications depends on factors such as lifestyle, environment, metabolism and genetics. It is not just a case of ‘one size fits all’. A specific intervention that works for one patient may not work in another. We use our extensive, in-depth biomedical expertise to help companies and healthcare professionals develop personalised interventions in the areas of metabolic and immune health.
Research in human subjects and the power of predictive models
TNO is constantly seeking new insights and technologies to ensure that animal testing is used as effectively as possible, and to refine, reduce, and replace it wherever possible. The animal models we develop and use can be shown to accurately mimic human disease processes. We also use non-animal models, such as computer models and organ-on-a-chip technology , which can improve and accelerate the development of new products, or we test these directly in human subjects . With all preclinical models, it is essential for us to know which elements of human physiology are accurately simulated and which are not.
Would you like to know more about our activities in the field of Biomedical Health or perhaps cooperate with us? Read the details below or get in touch with us.
Enabling tomorrow’s medicine: drug development
TNO works with public and private parties to create and implement innovative technologies that make the process of drug development – from laboratory to patient – more efficient. This will make it possible...
Microbiome: expertise and analysis
Determine microbiota composition in human subjects, and allow for accurate measurement and monitoring of microbiomes in various stages of scientific research to accelerate advancement and discovery. TNO...
Lifestyle as Medicine: Behavioural change is the key to curing lifestyle diseases
Lifestyle diseases cause considerable suffering and are financially costly for society. Preventing or curing these diseases enables many people to lead a better life. And when these people can do their...
Microtracer AMS: Accelerate your clinical development
De-risk and accelerate drug development with TNO’s exclusive auto-combustion-based AMS technology. Each Phase I, first-in-human (FIH) study can be a MIST and Mass Balance study, for faster, economical...
Preclinical NASH models
Nonalcoholic steatohepatitis (NASH) is one of the most prevalent chronic liver diseases. The number of patients suffering from NASH is increasing dramatically and is associated with metabolic syndrome,...
Joining forces for better mobile health in Kenya
Sub-Sahara Africa bears the highest disease burden in the world. Mobile health approaches are promising because mobile penetration rates are 80%. The NGO Amref Health Africa has been working on better...
Laboratory facilities for detection and inactivation SARS-CoV
The coronavirus has been dominating our lives for almost a year and has left its mark on our society and the global economy. TNO uses its knowledge power and works with partners on innovations to alleviate...
Prevention of chronic disease: understanding, monitoring and implementing interventions
TNO works on the reduction of chronic diseases in the multidisciplinary programme Prevention 2.0. The aim is to develop, together with partners, innovative interventions based on new insights into biological...
How healthy is a particular food product or diet? TNO Food and Health focuses on finding the answers. To this end we develop methods that make it possible to measure the health effects of foods. Manufacturers...
TNO and Janssen sign intention to develop new collaborations